Novo Nordisk to start phase III trial with tablet for Alzheimer's

Novo Nordisk plans to start a phase III trial with semaglutide against Alzheimer's disease during the first half of 2021, states the firm in a company announcement.

Photo: Novo Nordisk / PR

After many external research results with GLP-1 drugs used to treat Alzheimer's disease have been publicly presented, Novo Nordisk has opted to initiate its own research program, which the pharmaceutical company states on Wednesday afternoon in a company announcement.

Novo Nordisk expects to recruit around 3,700 patients with early-stage Alzheimer's, who will test the semaglutide treatment, which is advertised as a treatment for diabetes in either tablet form or in the form of injections.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs